首页> 外文会议>World congress on medical physics and biomedical engineering;International congress of the IUPESM >Evaluation on Lung Cancer Patients' Four-dimensional Treatment Plans Utilizing Biologically Effective Uniform Dose
【24h】

Evaluation on Lung Cancer Patients' Four-dimensional Treatment Plans Utilizing Biologically Effective Uniform Dose

机译:利用生物学有效均匀剂量对肺癌患者的四维治疗计划进行评估

获取原文

摘要

Four-dimensional (4D) radiotherapy is considered to be a feasible and ideal solution to accommodate intra-fractional respiratory motion during conformal radiation therapy. With explicit inclusion of the temporal changes in anatomy during the imaging, planning, and delivery of radiotherapy, 4D treatment planning in principle provides better dose conformity. However, the clinical benefits of developing 4D treatment plans in terms of tumor control rate and normal tissue complication probability as compared to other treatment plans based on CT images of a fixed respiratory phase remain mostly unproven. The aim of our study is to comprehensively evaluate 4D treatment planning for nine lung tumor cases with both physical and biological measures using biologically effective uniform dose (D) together with complication-free tumor control probability, P+. Based on the examined lung cancer patients and PTV margin applied, we found similar but not identical curves of DVH, and slightly different mean doses in tumor and normal tissues in all cases when comparing 4D, Po% and Pso% plans. When it comes to biological evaluations, we did not observe definitively PTV size dependence in P+ among these nine lung cancer patients with various sizes of PTV. Moreover, it is not necessary that 4D plans would have better target coverage or higher P+ as compared to a fixed phase IMRT plan.
机译:四维(4D)放射治疗被认为是在保形放射治疗过程中适应小范围内呼吸运动的可行且理想的解决方案。通过在放射治疗的成像,计划和交付过程中明确包括解剖结构的时间变化,原则上4D治疗计划可提供更好的剂量一致性。然而,与基于固定呼吸相的CT图像的其他治疗计划相比,开发4D治疗计划在肿瘤控制率和正常组织并发症发生率方面的临床益处仍未得到证实。我们研究的目的是使用生物学有效的统一剂量(D)以及无并发症的肿瘤控制概率P +,通过物理和生物学措施全面评估9例肺肿瘤病例的4D治疗计划。根据所检查的肺癌患者和应用的PTV幅度,在比较4D,Po%和Pso%计划时,在所有情况下,我们发现DVH曲线相似但不相同,并且在肿瘤和正常组织中的平均剂量略有不同。在生物学评估方面,我们没有在这9名不同大小PTV的肺癌患者中明确观察到P +中PTV大小的依赖性。此外,与固定阶段IMRT计划相比,4D计划没有必要具有更好的目标覆盖率或更高的P +。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号